A recent review in Clinical Advances in Hematology & Oncology spotlights promising developments in gastrointestinal oncology — especially for colorectal and pancreatic cancers, where late-stage diagnoses have long limited options. Highlights include fruquintinib for refractory metastatic CRC, the tucatinib + trastuzumab combination for HER2-positive CRC, and expanded uses for trifluridine-tipiracil in combination regimens.
Trending
- ‘Tremendous implications’: Hospital affiliation linked to higher-cost care (Healio)
- Omada Health Launches AI-Powered Meal Map to Transform Nutrition for Cardiometabolic Patients (HIT Consultant)
- 10 Must-Read Posts in GI Oncology This Week (OncoDaily)
- SCA Health expands GI footprint, physician network in 2025 (Becker’s GI & Endoscopy)
- 7 key numbers on the state of GI in 2025 (Becker’s GI & Endoscopy)
- White House Unveils ‘TrumpRx’ Drug-Buying Site and a Pfizer Pricing Deal (The Wall Street Journal)
- CADe for Colonoscopy: Positive and Negative Takeaways From Largest Real-World Study (GI & Endoscopy News)
- FDA OKs Tremfya for Ulcerative Colitis (GI & Hepatology News)
